TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26042362

Group type: EXPERIMENTAL
Intervention: CYT003 (0.3 mg)
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: CYT003 (1 mg)
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: CYT003 (2 mg)
Number of subjects: 365

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 365
Study: 23466396

Group type: COMPARATOR
Intervention: Normal Protein (NP; 14% of energy from protein)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Medium-High Protein (MHP; 25% of energy from protein)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: High Protein (HP; 50% of energy from protein)
Number of subjects: 25
Study: 21257196

Group type: EXPERIMENTAL
Intervention: RO-14 (1750-19950 IU of anti-FXa activity)
Number of subjects: 12
Study: 19589406

Group type: EXPERIMENTAL
Intervention: Fibrin seal
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Tachosil
Number of subjects: 300
Study: 16500175

Group type: EXPERIMENTAL
Intervention: 6-week neuromuscular training program
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (normal physical activity)
Number of subjects: 36
Study: 12733850

Group type: EXPERIMENTAL
Intervention: Sodium oxybate (3-9 gm/night)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 11072779

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (5 g creatine monohydrate, four times daily for 7 days)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (glucose capsules, same number as CS)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 9566142

Group type: EXPERIMENTAL
Intervention: Laser irradiated group (LG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blind irradiation group (BG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-treated control group (CG)
Number of subjects: 0
Study: 8468527

Group type: COMPARATOR
Intervention: High cholesterol diet (HC): 320 mg cholesterol/1000 kcal
Number of subjects: 30
Study: 3511944

Group type: EXPERIMENTAL
Intervention: new hydrocolloid dressing plus compression
Number of subjects: 34

Group type: COMPARATOR
Intervention: double layer bandage (inner paste bandage with zinc oxide paste and outer elastic bandage)
Number of subjects: 34
Study: 29070627

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) to the left motor cortex
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham stimulation (Control)
Number of subjects: 16
Study: 27110529

Group type: EXPERIMENTAL
Intervention: Ketamine (0.25 mg/kg) with paracetamol (15 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paracetamol (15 mg/kg) alone
Number of subjects: 0
Study: 24566243

Group type: EXPERIMENTAL
Intervention: 0.03 mg/kg midazolam
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg midazolam
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 90
Study: 21993613

Group type: EXPERIMENTAL
Intervention: Combined peer-expert narrative intervention
Number of subjects: 404

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 404
Study: 20490906

Group type: EXPERIMENTAL
Intervention: Terutroban
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1100
Study: 17709109

Group type: EXPERIMENTAL
Intervention: rosuvastatin 40 mg/day for 4 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study: 15796635

Group type: EXPERIMENTAL
Intervention: Problem-solving skills training (PSST), 8 sessions
Number of subjects: 430

Group type: COMPARATOR
Intervention: Usual psychosocial care (UPC)
Number of subjects: 430
Study: 12370562

Group type: EXPERIMENTAL
Intervention: Fish Oil (FO) 1.8 g of omega‐3 fatty acids x d(‐1)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Isoflavones (ISO) 120 mg soy isolate x d(‐1)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (PL) (Western fat blend and/or wheat flour)
Number of subjects: 22
Study: 10583448

Group type: EXPERIMENTAL
Intervention: Prazosin pretreatment (3 mg) plus smoking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atenolol pretreatment (50 mg) plus smoking
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo pretreatment plus smoking
Number of subjects: 0
Study: 8915027

Group type: EXPERIMENTAL
Intervention: Full-mouth disinfection (scaling and rootplaning in 2 visits within 24 h, tongue brushing with 1% chlorhexidine gel for 1 min, mouth rinsing with 0.2% chlorhexidine solution for 2 min, subgingival irrigation with 1% chlorhexidine gel)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (scaling and rootplaning at a 2-week interval)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Full-mouth disinfection
Number of subjects: 10
Study: 1908493

Group type: EXPERIMENTAL
Intervention: GHRH (1 microgram/kg iv)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: TRH (400 microgram iv)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 6351890

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine (4 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Clemastine (1 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 31387410

Group type: EXPERIMENTAL
Intervention: Fulranumab 3 mg Q4wk
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Fulranumab 1 mg Q4wk
Number of subjects: 245

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study: 28719500

Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HB-PRP-T vaccine
Number of subjects: 1375

Group type: COMPARATOR
Intervention: Control vaccine (DTaP-HB-IPV//PRP-T)
Number of subjects: 1375

Group type: EXPERIMENTAL
Intervention: Antipyretics
Number of subjects: 1375

Group type: EXPERIMENTAL
Intervention: Extra (oral) polio vaccination
Number of subjects: 1375

Group type: EXPERIMENTAL
Intervention: PCV7 and rotavirus vaccine
Number of subjects: 1375
Study: 26595100

Group type: EXPERIMENTAL
Intervention: Average change across visits in mean 2-hour blood glucose level after meals
Number of subjects: 1115

Group type: EXPERIMENTAL
Intervention: Average change across visits in hemoglobin A1c level
Number of subjects: 1115

Group type: EXPERIMENTAL
Intervention: Absence of a history of stroke or acute MI
Number of subjects: 1115

Group type: EXPERIMENTAL
Intervention: Fasting blood glucose and randomized insulin treatment strategy
Number of subjects: 1115
Study: 25079933

Group type: EXPERIMENTAL
Intervention: 7.5 mg prednisolone daily for 2 years (P-group; n=108)
Number of subjects: 225

Group type: COMPARATOR
Intervention: No prednisolone (NoP-group; n=117)
Number of subjects: 225
Study: 21503648

Group type: EXPERIMENTAL
Intervention: Target preview delay of 150 ms before perturbation onset
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Target preview delay of 70 ms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short-latency epoch (R1; 20-45 ms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-latency epoch (45-105 ms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Voluntary epoch (120-180 ms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Target appeared after perturbation onset (target PD = +90 ms)
Number of subjects: 0
Study: 19996018

Group type: EXPERIMENTAL
Intervention: TEVAR (Thoracic Endovascular Aortic Repair) in addition to optimal medical therapy (n=72)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Optimal medical therapy alone (n=68)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: TEVAR (Thoracic Endovascular Aortic Repair)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Optimal medical therapy alone
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Combined end point of aorta-related death and progression (including conversion or additional endovascular or open surgery)
Number of subjects: 140
Study: 17664199

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (15 mg x kg(‐1) before infusion of heparin and 15 mg x kg(‐1) after protamine infusion)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 66
Study: 15548814

Group type: EXPERIMENTAL
Intervention: Niacin 500 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Niacin 250 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Niacin (both doses)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11314677

Group type: EXPERIMENTAL
Intervention: 100% daily dose of methadone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 50% daily dose of methadone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Methadone (both doses)
Number of subjects: 20
Study: 9213939

Group type: EXPERIMENTAL
Intervention: Operative intervention
Number of subjects: 75

Group type: COMPARATOR
Intervention: Soft-tissue operation (tenotomy)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Open neurolysis
Number of subjects: 75
Study: 8200249

Group type: EXPERIMENTAL
Intervention: Octreotide (1.25 micrograms/kg subcutaneously)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2822203

Group type: EXPERIMENTAL
Intervention: Diet with little or no sugar and high in unrefined carbohydrate
Number of subjects: 352

Group type: COMPARATOR
Intervention: Diet unrestricted in sugar and low in fibre
Number of subjects: 352
Study: 30189840

Group type: EXPERIMENTAL
Intervention: Topical steroid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27091900

Group type: EXPERIMENTAL
Intervention: ivabradine
Number of subjects: 46

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 46
Study: 25517733

Group type: EXPERIMENTAL
Intervention: 360 µg TNF-K (3 injections)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TNF-K (all doses)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (3 injections)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Patients with anti-TNF antibody response
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Patients without anti-TNF antibody response
Number of subjects: 40
Study: 22813832

Group type: EXPERIMENTAL
Intervention: Telephone support oriented by accelerometer measurements
Number of subjects: 29

Group type: COMPARATOR
Intervention: Accelerometer (control group)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Accelerometer (intervention group)
Number of subjects: 29
Study: 20362199

Group type: EXPERIMENTAL
Intervention: Serotype 9V
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-absorption using serotype 9V
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine (PCV) doses
Number of subjects: 0
Study: 17845107

Group type: EXPERIMENTAL
Intervention: Telephone-administered cognitive-behavioral therapy (T-CBT) for 16 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Telephone-administered supportive emotion-focused therapy (T-SEFT) for 16 weeks
Number of subjects: 0
Study: 15675924

Group type: EXPERIMENTAL
Intervention: Troposmia group (strawberry scented facemask with sevoflurane)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (standard facemask without olfactory modification)
Number of subjects: 64
Study: 12025733

Group type: EXPERIMENTAL
Intervention: Multichannel recording of the interhemispheric amplitude distribution of the N70 of the onset VEP
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Electrode pair over the temporo-parietal junction
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Cumulative abnormality taken over all lateral electrode pairs
Number of subjects: 47
Study: 10400054

Group type: EXPERIMENTAL
Intervention: Idoxifene 2.5 mg/day
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Idoxifene 5 mg/day
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Idoxifene 10 mg/day
Number of subjects: 331

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Idoxifene (all doses)
Number of subjects: 331
Study: 7575066

Group type: EXPERIMENTAL
Intervention: Epoetin alfa, 150 U/kg, administered subcutaneously three times per week for 6 weeks
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Epoetin alfa, 150 U/kg, administered to patients who were originally receiving placebo for 6 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo administered subcutaneously three times per week for 6 weeks
Number of subjects: 25
Study: 1702338

Group type: EXPERIMENTAL
Intervention: Ethamsylate (Dicynene)
Number of subjects: 44
Study: 6249137

Group type: EXPERIMENTAL
Intervention: Electrostimulation analgesia (ESA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Neuroleptanalgesia (NLA)
Number of subjects: 30
Study: 31880315

Group type: EXPERIMENTAL
Intervention: ROC-guided survival trees and ensembles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ensemble procedure based on averaging martingale estimating equations
Number of subjects: 0
Study: 31875047

Group type: EXPERIMENTAL
Intervention: 12-min treadmill running
Number of subjects: 40

Group type: COMPARATOR
Intervention: Walking
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Running
Number of subjects: 40
Study: 27862264

Group type: EXPERIMENTAL
Intervention: Every three-hour oral feeding schedule
Number of subjects: 55

Group type: COMPARATOR
Intervention: Every six-hour oral feeding schedule
Number of subjects: 55
Study: 25357148

Group type: EXPERIMENTAL
Intervention: Partial body weight‐support treadmill training at 10% inclination
Number of subjects: 28

Group type: COMPARATOR
Intervention: Partial body weight‐support treadmill training with no inclination
Number of subjects: 28
Study: 23286782

Group type: EXPERIMENTAL
Intervention: Protein and Ca drink (500 ml)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Low-fat milk
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 16
Study: 21079374

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral stress management program
Number of subjects: 124

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 124
Study: 19960160

Group type: EXPERIMENTAL
Intervention: Coitus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orgasm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coitus and Orgasm
Number of subjects: 0
Study: 15930400

Group type: EXPERIMENTAL
Intervention: Computerized decision support tool
Number of subjects: 693

Group type: COMPARATOR
Intervention: Memory-based triage by nurses
Number of subjects: 693
Study: 12393770

Group type: EXPERIMENTAL
Intervention: Hextend
Number of subjects: 63

Group type: COMPARATOR
Intervention: Lactated Ringers solution (RL)
Number of subjects: 63

Group type: COMPARATOR
Intervention: HES 130/0.4
Number of subjects: 63
Study: 10342804

Group type: EXPERIMENTAL
Intervention: Video-enhanced, computer-assisted, self-administered interviews (V-CASI)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Face-to-face interviews (FTFI)
Number of subjects: 280
Study: 7773829

Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment
Number of subjects: 0
Study: 2387608

Group type: EXPERIMENTAL
Intervention: Preanaesthetic medication with atropine and retrobulbar injection of xylocaine
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Preanaesthetic medication with atropine
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Retrobulbar injection of xylocaine
Number of subjects: 53

Group type: COMPARATOR
Intervention: No preanaesthetic medication with atropine or retrobulbar block with xylocaine
Number of subjects: 53
Study: 7104169

Group type: EXPERIMENTAL
Intervention: Food intake
Number of subjects: 6
Study: 31945165

Group type: EXPERIMENTAL
Intervention: 20-week participatory ergonomics intervention consisting of three training workshops
Number of subjects: 190

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: 20-week participatory ergonomics intervention
Number of subjects: 190
Study: 30817193

Group type: EXPERIMENTAL
Intervention: Multimodal assessment including imaging characteristics and hormonal measurements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biopsy, surgical or medical therapy, and longitudinal surveillance
Number of subjects: 0
Study: 28763464

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 16

Group type: COMPARATOR
Intervention: Simethicone and activated charcoal (SC; Carbosylane)
Number of subjects: 16
Study: 25057116

Group type: EXPERIMENTAL
Intervention: Surgical discectomy
Number of subjects: 1244

Group type: COMPARATOR
Intervention: Usual nonoperative care
Number of subjects: 1244

Group type: EXPERIMENTAL
Intervention: Combined randomized and observational cohorts (surgery)
Number of subjects: 1244

Group type: COMPARATOR
Intervention: Combined randomized and observational cohorts (nonoperative care)
Number of subjects: 1244
Study: 23431966

Group type: EXPERIMENTAL
Intervention: PUVA
Number of subjects: 36

Group type: COMPARATOR
Intervention: PUVAsol
Number of subjects: 36
Study: 21830265

Group type: EXPERIMENTAL
Intervention: Tailored patient preference intervention including educational and motivational components, simplified dosing regimes, and practical reminders (pill dispensers)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Tailored patient preference intervention
Number of subjects: 71
Study: 19137306

Group type: EXPERIMENTAL
Intervention: 3.0 T MRI
Number of subjects: 24

Group type: COMPARATOR
Intervention: 1.5 T MRI
Number of subjects: 24
Study: 17204318

Group type: EXPERIMENTAL
Intervention: Network-model managed care health plan
Number of subjects: 442

Group type: COMPARATOR
Intervention: Community-based practices (CBP)
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Both strategies
Number of subjects: 442
Study: 16246820

Group type: EXPERIMENTAL
Intervention: Neck muscle endurance training
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Neck muscle strength training
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 180
Study: 11755939

Group type: EXPERIMENTAL
Intervention: Experimental yoghurt (3 cups daily providing 1 g of plant stanols)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo yoghurt (3 cups daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Experimental yoghurt
Number of subjects: 60
Study: 10523963

Group type: EXPERIMENTAL
Intervention: Deoxinate therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enkad
Number of subjects: 0
Study: 7537797

Group type: EXPERIMENTAL
Intervention: Hormonal therapy
Number of subjects: 648
Study: 1709002

Group type: EXPERIMENTAL
Intervention: 3-isobutyl-1-methylxanthine (IBMX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study: 7263143

Group type: EXPERIMENTAL
Intervention: CogentinTM (benztropine mesylate) at increasing doses (maximum 2 mg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 30989965

Group type: EXPERIMENTAL
Intervention: Bushen Huoxue Anshen Fang (Traditional Chinese Medicine)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 67
Study: 28980140

Group type: EXPERIMENTAL
Intervention: Dexamethasone (10 mg) and paracetamol (1000 mg)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Dexamethasone (10 mg) alone
Number of subjects: 226
Study: 26476354

Group type: EXPERIMENTAL
Intervention: Ultra mini percutaneous nephrolithotomy
Number of subjects: 94
Study: 25041377

Group type: EXPERIMENTAL
Intervention: PF-05280014
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: trastuzumab-EU
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: trastuzumab-US
Number of subjects: 105
Study: 22021080

Group type: EXPERIMENTAL
Intervention: Melanoma peptides (gp100, MART-1, tyrosinase) with GM-CSF, IFN-α2b or both
Number of subjects: 37

Group type: COMPARATOR
Intervention: GM-CSF and/or IFN-α2b
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: CD8(+) tet(+) T cells
Number of subjects: 37

Group type: COMPARATOR
Intervention: IFN-γ ELISPOT assays
Number of subjects: 37
Study: 19352588

Group type: EXPERIMENTAL
Intervention: Sargramostim 2 microg/kg per day for 4 weeks (Step 1)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Sargramostim 6 microg/kg per day for 4 weeks (Step 2)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Sargramostim 6 microg/kg per day (Step 2)
Number of subjects: 11
Study: 17234505

Group type: EXPERIMENTAL
Intervention: Long-chain triacylglycerols (LCTs)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Medium-chain and long-chain triacylglycerols (MCTs/LCTs)
Number of subjects: 9
Study: 15222836

Group type: EXPERIMENTAL
Intervention: Preparing for the Drug Free Years program
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Iowa Strengthening Families Program
Number of subjects: 373

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 373
Study: 12202439

Group type: EXPERIMENTAL
Intervention: Expectant management
Number of subjects: 122

Group type: COMPARATOR
Intervention: Surgical evacuation
Number of subjects: 122
Study: 9718903

Group type: EXPERIMENTAL
Intervention: Sickle cell disease (SCD)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (CSS)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: SCD with defective GH secretion
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: SCD
Number of subjects: 28
Study: 8624428

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PF) treated spermatozoa
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control spermatozoa
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PF) treated embryos
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control embryos
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both PF and control embryos
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PF)
Number of subjects: 49
Study: 2750998

Group type: EXPERIMENTAL
Intervention: Acetazolamide (1 g, intravenous)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 23
Study: 993455

Group type: EXPERIMENTAL
Intervention: Subjects who believed they had consumed an alcoholic beverage
Number of subjects: 40

Group type: COMPARATOR
Intervention: Subjects who believed they had consumed a nonalcoholic beverage
Number of subjects: 40
Study: 31692244

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 269

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269